MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
7.61
+0.35
+4.82%
After Hours: 7.61 0 0.00% 16:02 12/01 EST
OPEN
7.28
PREV CLOSE
7.26
HIGH
7.68
LOW
7.26
VOLUME
308.28K
TURNOVER
0
52 WEEK HIGH
14.34
52 WEEK LOW
5.27
MARKET CAP
334.80M
P/E (TTM)
4.133
1D
5D
1M
3M
1Y
5Y
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) large institutional owners must be happy as stock continues to impress, up 11% over the past week
Institutional investors own 43% of voyager therapeutics, inc. (nasdaq:vygr) the top 6 shareholders of the company own 52% of the stock. The company has a high level of institutional ownership, but the majority of shares are owned by the top 6. Hedge funds are the biggest shareholders, with neurocrine biosciences, inc., the largest shareholder. Voyager therapeutics has a history of positive earnings and revenue growth, but there are three warning signs of insider selling.
Simply Wall St · 1d ago
Overview Of Value Stocks In The Healthcare Sector
A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Low p/e multiples are a good indicator that a company is undervalued. Benzinga insights has selected five notable value stocks in the healthcare sector.
Benzinga · 6d ago
Weekly Report: what happened at VYGR last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at VYGR last week (1113-1117)?
Weekly Report · 11/20 09:20
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers bone biologics (nasdaq:bblg) stock increased by 64.3% to $0.89 during thursday's pre-market session. Invivo therapeutics hldg stock rose 24.66% after the company's q3 earnings came out. Heart test laboratories shares increased by 14.33% and biovie stock rose by 13.33%.
Benzinga · 11/16 13:06
Weekly Report: what happened at VYGR last week (1106-1110)?
Weekly Report · 11/13 09:19
Voyager Therapeutics (VYGR) Receives a Buy from Truist Financial
TipRanks · 11/09 02:30
Voyager Therapeutics: A Promising Buy with Strong Potential in CNS Platform and Alzheimer’s Disease Sector
TipRanks · 11/08 12:50
More
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines. Its gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. It has developed an AAV capsid discovery platform called Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACERTM) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (BBB). Its pipeline programs include superoxide dismutase 1 (SOD1), gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease.

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.